Skip to main content
Top
Published in: International Journal of Hematology 1/2016

01-07-2016 | Original Article

Screening frequency, incidence and pattern of heparin-induced thrombocytopenia syndrome at a large tertiary institution

Authors: Hae Tha Mya, Hui Ming Tay, Shien Wen Gan, Shilpa Surendran, Shu Hui Yeang, Cynthia Ciwei Lim, HuiLin Choong, Lai Heng Lee, Heng Joo Ng

Published in: International Journal of Hematology | Issue 1/2016

Login to get access

Abstract

Increasing awareness and availability of tests for anti-PF4/heparin complex antibodies has raised concerns about indiscriminate testing and inappropriate diagnosis of heparin-induced thrombocytopenia. A retrospective review of HITS testing at a large tertiary centre was performed to determine test patterns and incidence of HITS. Records of anti-PF4 tests over 4 years were reviewed. Positive results were matched against patient medical records and records of heparin utilisation for the diagnosis of HITS. Total of 33,308 patients (9.89 % of admissions) were exposed to at least 1 day of unfractionated heparin (UFH) or low molecular weight heparin (LMWH). Of 346 anti-PF4 antibody assays performed, 52 (15 %) were positive. Seventeen patients (4.9 % of total) were determined to have HITS. Of these, 13 cases (76 %) were patients who were initiated on haemodialysis via central venous catheters. Five patients (29 %) subsequently experienced thrombosis. The rate of HITS in patients given UFH was 0.33 %. HITS occurred in only one patient given LMWH. Of 1337 patients with chronic renal failure initiated on long term haemodialysis, the incidence of HITS was 0.97 %. Despite increased awareness of HITS, testing frequency remains conservative. An overwhelming majority of HITS cases were diagnosed among patients initiated on haemodialysis.
Literature
1.
go back to reference Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet. 1973;136(3):409–16.PubMed Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet. 1973;136(3):409–16.PubMed
2.
go back to reference Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood. 2008;112(7):2607–16.CrossRefPubMed Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood. 2008;112(7):2607–16.CrossRefPubMed
3.
go back to reference Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502–7.CrossRefPubMed Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502–7.CrossRefPubMed
4.
go back to reference Tapan U, Bolla S, Daglilar ES, Chang S, Kozyreva O. Outcome of patients with positive heparin-platelet factor-4 antibodies: a retrospective multi-institutional observational study. Platelets. 2015;26(7):661–4.CrossRefPubMed Tapan U, Bolla S, Daglilar ES, Chang S, Kozyreva O. Outcome of patients with positive heparin-platelet factor-4 antibodies: a retrospective multi-institutional observational study. Platelets. 2015;26(7):661–4.CrossRefPubMed
5.
go back to reference Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006;107(6):2346–53.CrossRefPubMedPubMedCentral Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006;107(6):2346–53.CrossRefPubMedPubMedCentral
6.
go back to reference Padmanabhan A, Jones CG, Bougie DW, Curtis BR, McFarland JG, Wang D, et al. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. Blood. 2015;125(1):155–61.CrossRefPubMedPubMedCentral Padmanabhan A, Jones CG, Bougie DW, Curtis BR, McFarland JG, Wang D, et al. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. Blood. 2015;125(1):155–61.CrossRefPubMedPubMedCentral
7.
go back to reference Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost. 2007;5(8):1666–73.CrossRefPubMed Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost. 2007;5(8):1666–73.CrossRefPubMed
8.
go back to reference Cines DB, Rauova L, Arepally G, Reilly MP, McKenzie SE, Sachais BS, et al. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher. 2007;22(1):31–6.CrossRefPubMed Cines DB, Rauova L, Arepally G, Reilly MP, McKenzie SE, Sachais BS, et al. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher. 2007;22(1):31–6.CrossRefPubMed
9.
go back to reference Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med. 2005;146(6):341–6.CrossRefPubMed Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med. 2005;146(6):341–6.CrossRefPubMed
10.
go back to reference Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710–5.CrossRefPubMed Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710–5.CrossRefPubMed
11.
go back to reference Prandoni P, Siragusa S, Girolami B, Fabris F, Group BI. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood. 2005;106(9):3049–54.CrossRef Prandoni P, Siragusa S, Girolami B, Fabris F, Group BI. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood. 2005;106(9):3049–54.CrossRef
12.
go back to reference Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101(8):2955–9.CrossRefPubMed Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101(8):2955–9.CrossRefPubMed
13.
go back to reference Greinacher A, Alban S, Omer-Adam MA, Weitschies W, Warkentin TE. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res. 2008;122(2):211–20.CrossRefPubMed Greinacher A, Alban S, Omer-Adam MA, Weitschies W, Warkentin TE. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res. 2008;122(2):211–20.CrossRefPubMed
14.
go back to reference Locke CF, Dooley J, Gerber J. Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar. Thromb J. 2005;3(1):4.CrossRefPubMedPubMedCentral Locke CF, Dooley J, Gerber J. Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar. Thromb J. 2005;3(1):4.CrossRefPubMedPubMedCentral
15.
go back to reference Warkentin TE, Cook RJ, Marder VJ, Greinacher A. Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost. 2010;8(3):504–12.CrossRefPubMed Warkentin TE, Cook RJ, Marder VJ, Greinacher A. Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost. 2010;8(3):504–12.CrossRefPubMed
16.
go back to reference Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993;69(4):344–50.PubMed Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993;69(4):344–50.PubMed
17.
go back to reference Harenberg J, Huhle G, Giese C, Wang LC, Feuring M, Song XH, et al. Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2000;109(1):182–6.CrossRefPubMed Harenberg J, Huhle G, Giese C, Wang LC, Feuring M, Song XH, et al. Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2000;109(1):182–6.CrossRefPubMed
18.
go back to reference Cuker A. Heparin-induced thrombocytopenia (HIT) in 2011: an epidemic of overdiagnosis. Thromb Haemost. 2011;106(6):993–4.CrossRefPubMed Cuker A. Heparin-induced thrombocytopenia (HIT) in 2011: an epidemic of overdiagnosis. Thromb Haemost. 2011;106(6):993–4.CrossRefPubMed
19.
go back to reference Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th edn, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S–530S.CrossRefPubMedPubMedCentral Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th edn, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S–530S.CrossRefPubMedPubMedCentral
20.
go back to reference Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH. Haemostasis sascotisota. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost. 2011;9(12):2498–500.CrossRefPubMed Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH. Haemostasis sascotisota. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost. 2011;9(12):2498–500.CrossRefPubMed
21.
go back to reference Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759–65.CrossRefPubMed Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759–65.CrossRefPubMed
22.
go back to reference Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304–12.CrossRefPubMed Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304–12.CrossRefPubMed
23.
go back to reference Chan CM, Woods CJ, Warkentin TE, Sheppard JA, Shorr AF. The role for optical density in heparin-induced thrombocytopenia: a cohort study. Chest. 2015;148(1):55–61.CrossRefPubMed Chan CM, Woods CJ, Warkentin TE, Sheppard JA, Shorr AF. The role for optical density in heparin-induced thrombocytopenia: a cohort study. Chest. 2015;148(1):55–61.CrossRefPubMed
24.
go back to reference Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–94.CrossRefPubMed Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–94.CrossRefPubMed
25.
go back to reference Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest. 2007;131(6):1644–9.CrossRefPubMed Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest. 2007;131(6):1644–9.CrossRefPubMed
26.
go back to reference Carrier M, Knoll GA, Kovacs MJ, Moore JC, Fergusson D, Rodger MA. The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis. Thromb Res. 2007;120(2):215–20.CrossRefPubMed Carrier M, Knoll GA, Kovacs MJ, Moore JC, Fergusson D, Rodger MA. The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis. Thromb Res. 2007;120(2):215–20.CrossRefPubMed
27.
go back to reference Palomo I, Pereira J, Alarcón M, Díaz G, Hidalgo P, Pizarro I, et al. Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis. J Clin Lab Anal. 2005;19(5):189–95.CrossRefPubMed Palomo I, Pereira J, Alarcón M, Díaz G, Hidalgo P, Pizarro I, et al. Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis. J Clin Lab Anal. 2005;19(5):189–95.CrossRefPubMed
28.
go back to reference Zhao D, Sun X, Yao L, Lin H, Li J, Zhao J, et al. The clinical significance and risk factors of anti-platelet factor 4/heparin antibody on maintenance hemodialysis patients: a two-year prospective follow-up. PLoS One. 2013;8(4):e62239.CrossRefPubMedPubMedCentral Zhao D, Sun X, Yao L, Lin H, Li J, Zhao J, et al. The clinical significance and risk factors of anti-platelet factor 4/heparin antibody on maintenance hemodialysis patients: a two-year prospective follow-up. PLoS One. 2013;8(4):e62239.CrossRefPubMedPubMedCentral
29.
go back to reference Chan KM, Cheung CY, Chau KF. Heparin-induced thrombocytopenia due to heparin lock in a hemodialysis patient: a case report. Hemodial Int. 2014;18(2):555–8.CrossRefPubMed Chan KM, Cheung CY, Chau KF. Heparin-induced thrombocytopenia due to heparin lock in a hemodialysis patient: a case report. Hemodial Int. 2014;18(2):555–8.CrossRefPubMed
30.
go back to reference Ng HJ, Than H, Teo EC. First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia. Thromb Res. 2015;135(1):205–7.CrossRefPubMed Ng HJ, Than H, Teo EC. First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia. Thromb Res. 2015;135(1):205–7.CrossRefPubMed
Metadata
Title
Screening frequency, incidence and pattern of heparin-induced thrombocytopenia syndrome at a large tertiary institution
Authors
Hae Tha Mya
Hui Ming Tay
Shien Wen Gan
Shilpa Surendran
Shu Hui Yeang
Cynthia Ciwei Lim
HuiLin Choong
Lai Heng Lee
Heng Joo Ng
Publication date
01-07-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2013-3

Other articles of this Issue 1/2016

International Journal of Hematology 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine